Formosa Pharmaceuticals Inc 6838
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
-
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.
-
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States
-
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery
Trading Information
- Previous Close Price
- TWD 42.75
- Day Range
- TWD 42.85–44.50
- 52-Week Range
- TWD 36.90–47.70
- Bid/Ask
- TWD 43.90 / TWD 44.00
- Market Cap
- TWD 6.63 Bil
- Volume/Avg
- 425,100 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 42.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Formosa Pharmaceuticals Inc is a late-preclinical and early-clinical stage biopharmaceutical company with focus in the indications of ophthalmology, oncology, and anti-infectives.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 12
- Website
- https://www.formosapharma.com
Comparables
Valuation
|
Metric
|
6838
|
4743
|
06891
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.67 | 4.97 | 3.19 |
Price/Sales | 42.92 | 883.81 | 5,531.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
6838
4743
06891
Financial Strength
|
Metric
|
6838
|
4743
|
06891
|
|---|---|---|---|
Quick Ratio | 6.43 | 44.25 | 16.22 |
Current Ratio | 6.67 | 45.27 | 16.50 |
Interest Coverage | −67.16 | −377.23 | −111.98 |
Quick Ratio
6838
4743
06891
Profitability
|
Metric
|
6838
|
4743
|
06891
|
|---|---|---|---|
Return on Assets (Normalized) | −15.94% | −10.96% | −5.13% |
Return on Equity (Normalized) | −23.61% | −11.75% | −5.43% |
Return on Invested Capital (Normalized) | −23.87% | −12.47% | −6.90% |
Return on Assets
6838
4743
06891
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dvmfrpssb | Mwvj | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jzqslcx | Yyvmdf | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kcxmrmfy | Xzzbmv | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vzcdnflj | Tmbbdw | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Kztypztn | Yjhm | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Mgbyqjh | Mlkg | $28.0 Bil | |||
| Moderna Inc
MRNA
| Dpzrnrq | Dqv | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Mpzzyhrp | Gykf | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pqgbqbrh | Ltpymld | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Wgfsbsvhln | Jqbgrgh | $12.6 Bil |
United States